Genentech’s Ocrevus Dominates the Progressive Multiple Sclerosis Market, Although Emerging Agents Could Threaten its Long-Term Reign, According to Patient Chart Data from Spherix Global Insights

EXTON, Pa., Oct. 27, 2020 /PRNewswire/ — While the segment of multiple sclerosis (MS) patients with progressive disease remains underserved, numerous recent approvals for relapsing MS (RMS) — including active secondary progressive MS (SPMS) — have enhanced neurologists’ ability to treat…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.